Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
OPB-111077 by Otsuka Pharmaceutical for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
OPB-111077 by Otsuka Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
OPB-111077 by Otsuka Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
OPB-111077 by Otsuka Pharmaceutical for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
OPB-111077 is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...